Myron Kaplan - May 17, 2022 Form 4 Insider Report for CorMedix Inc. (CRMD)

Role
Director
Signature
/s/ Myron Kaplan
Stock symbol
CRMD
Transactions as of
May 17, 2022
Transactions value $
$18,900
Form type
4
Date filed
5/18/2022, 05:21 PM
Previous filing
Feb 23, 2022
Next filing
Jan 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRMD Common Stock Purchase $18.9K +5K +3.23% $3.78 160K May 17, 2022 Direct F1
holding CRMD Common Stock 20K May 17, 2022 Spouse F2
holding CRMD Common Stock 10K May 17, 2022 Spouse as Guardian for Grandchildren F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CRMD Stock Option (Right to Buy Common Stock) 20K May 17, 2022 Common Stock 20K $4.03 Direct F3
holding CRMD Stock Option (Right to Buy Common Stock) 30K May 17, 2022 Common Stock 30K $8.32 Direct F4
holding CRMD Stock Option (Right to Buy Common Stock) 15K May 17, 2022 Common Stock 15K $5.63 Direct F5
holding CRMD Stock Option (Right to Buy Common Stock) 15K May 17, 2022 Common Stock 15K $8.30 Direct F6
holding CRMD Stock Option (Right to(Right to Buy Common Stock) 8K May 17, 2022 Common Stock 8K $2.85 Direct F7
holding CRMD Stock Option (Right to Buy Common Stock) 8K May 17, 2022 Common Stock 8K $11.20 Direct F8
holding CRMD Stock Option (Right to Buy Common Stock) 1K May 17, 2022 Common Stock 10K $21.40 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.77 to $3.79, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
F2 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F3 These options were granted on 2/22/2022. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board.
F4 These options were granted on 1/11/2021. These options are fully vested.
F5 These options were granted on 2/25/2020. These options are fully vested.
F6 These options were granted on 1/10/2019. These options are fully vested.
F7 These options were granted on 2/16/2018. These options are fully vested.
F8 These options were granted on 2/21/2017. These options are fully vested.
F9 These options were granted on 4/28/2016. These options are fully vested.